Cardiac allograft vasculopathy: A review

Circulation

Volumn 96, Issue 6, 1997, Pages 2069-2077

  Weis, Michael ^a   Von Scheidt, Wolfgang ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Coronary disease; Endothelium; Transplantation; Vasculopathy

Indexed keywords

ANGIOPEPTIN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE; PREDNISONE; RAPAMYCIN; SIMVASTATIN; TACROLIMUS;

ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; CELL DEATH; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; ENDOTHELIUM INJURY; GRAFT REJECTION; HEART MUSCLE REVASCULARIZATION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVASCULAR ULTRASOUND; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; RECIPIENT; REVIEW; VASCULAR DISEASE;

EID: 0030823697     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.6.2069     Document Type: Review

References (115)

1. Kaye MP. The Registry of the International Society for Heart and Lung Transplantation: Tenth Official Report - 1993. J Heart Lung Transplant. 1993;12:541-548.
2. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant. 1992;11:S38-S44.
3. Gao SZ, Hunt SA, Schroeder JS, Alderman E, Hill IR, Stinson EB. Does rapidity of development of transplant coronary artery disease portend a worse prognosis? J Heart Lung Transplant. 1994; 13:1119-1124.
4. Costanzo MR, Naftel DC, Pritzker MR, Hellman JK, Boehmer JP, Brozena SC, Dec WG, Ventura HO, Kirklin JK, Bourge RC, Miller LW. Heart transplant coronary artery disease detected by angiography: a multi-institutional study. J Heart Lung Transplant. 1996;15:S39. Abstract.
5. Yeung AC, Davis SF, Hauptmann PJ, Kobashigawa JA, Miller LW, Valantine HA, Ventura HO, Wiedermann J, Wilensky R. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant. 1995;14:S215-S220.
6. Pucci AM, Forbes RDC, Billingham ME. Pathologic features in long-term cardiac allograft. J Heart Transplant. 1990;9:339-345.
7. McManus BM, Horley KJ, Wilson JE, Malcom GT, Kendall TJ, Miles RR, Winters GL, Costanzo MR, Miller LL, Radio SJ. Prominence of coronary arterial wall lipids in human heart allografts. Am J Pathol. 1995;147:293-308.
8. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 1989;8:349-359.
9. Neish AS, Loh E, Schoen FJ. Myocardial changes in cardiac transplant-associated coronary arteriosclerosis: potential for timely diagnosis. J Am Coll Cardiol. 1992;19:586-592.
10. Billingham ME. Pathology of graft vascular disease after heart and heart-lung transplantation and its relationship to obliterative bronchiolitis. Transplant Proc. 1995;27:2013-2016.
11. Treasure CB, Alexander RW. Relevance of vascular biology to the ischemic syndromes of coronary atherosclerosis. Cardiovasc Drugs Ther. 1995;9:13-19.
12. Libby P, Swanson SJ, Tanaka H. Immunopathology of coronary arteriosclerosis in transplanted hearts. J Heart Lung Transplant. 1992;11:5-6.
13. Smith JD, Pomerance A, Burke M, Yacoub M, Rose ML. Effect of HLA matching on graft function and long-term survival after cardiac transplantation: results of a large single center study. J Heart Lung Transplant. 1995;14(part 2):S40. Abstract.
14. Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MA. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease. J Heart Lung Transplant. 1994;13:1381-1392.
15. Duquesnoy RJ, Demetris AJ. Immunopathology of cardiac transplant rejection. Curr Opin Cardiol. 1995;10:193-206.
16. Hayry P, Renkonen R, Leszczynski D, Mattila P, Tiisala S, Halltunnen J, Turunen JP, Partanen T, Rinta K. Local events in graft rejection. Transplant Proc. 1989;21:3716-3720.
17. Ardehali A, Laks H, Drinkwater DC, Ziv E, Drake TA. Vascular cell adhesion molecule-1 is induced on vascular endothelial and medial smooth muscle cells in experimental cardiac allograft vasculopathy. Circulation. 1995;92:450-456.
18. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc. 1995;27: 1939-1940.
19. Rabinovitch M, Molossi S, Clausell N. Cytokine-mediated fibronectin production and transendothelial migration of lymphocytes in the mechanism of cardiac allograft vascular disease: efficacy of novel therapeutic approaches. J Heart Lung Transplant. 1995;14:S116-S123.
20. Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation. 1995;91:2703-2711.
21. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest. 1996;74:921-931.
22. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Circ Res. 1996;79:748-756.
23. Szabolcs M, Mitchler RE, Yang Y, Aji W, Roy D, Athan E, Sciacca RR, Minanov OP, Cannon PJ. Apoptosis of cardiac myocytes during cardiac allograft rejection: relation to induction of nitric oxide synthase. Circulation. 1996;94:1665-1673.
24. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnoswky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arterioscleroses. Circulation. 1995;92:457-464.
25. Gibbons GH. The pathogenesis of graft vascular disease: implications of vascular remodeling. J Heart Lung Transplant. 1995;14: S149-S158.
26. Lim TT, Botas J, Liang DH, Schroeder JS, Oesterle SN, Popp RL, Yeung AC. Does compensatory dilation occur in heart transplant recipients with progressive coronary artery disease? Serial studies using intravascular ultrasound. Circulation. 1994;90(part 2):3439. Abstract.
27. von Scheidt W, Erdmann E. Dilated angiopathy: a specific subtype of allograft coronary artery disease. J Heart Lung Transplant. 1991; 10:698-703.
28. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant. 1992;11:S124-S132.
29. Escobar A, Ventura HO, Stapleton DD, Mehra MR, Ramee SR, Collins TC, Jain SP, White CJ. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol. 1994;74:1042-1046.
30. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol. 1996;28:673-679.
31. Hauptmann PJ, Davis SF, Miller L, Yeung AC. The role of nonimmune risk factors in the development and progression of graft arteriosclerosis: preliminary insights from a multicenter intravascular ultrasound study. J Heart Lung Transplant. 1995;14: S238-S242.
32. Kemma MS, Valantine HA, Hunt SA, Schroeder JS, Chen Y-D, Reaven GM. Metabolic risk factors for atherosclerosis in heart transplant recipients. Am Heart J. 1994;128:68-72.
33. Kugiyama K, Kerns SA, Morrisett JD, Robbers R, Henry PD. Impairment of endothelium dependent arterial relaxation of arterial smooth muscle by lysolecithin in modified low density lipoproteins. Nature. 1990;344:160-162.
34. Seiler C, Hess OM, Buechi M, Suter TM, Krayenbuehl HP. Influence of serum cholesterol and other coronary risk factors on vasomotion of angiographically normal coronary arteries. Circulation. 1993;88:2139-2148.
35. Hartmann A, Weis M, Olbrich HG, Cieslinski G, Schacherer C, Burger W, Beyersdorf F, Schräder R. Endothelium-dependent and endothelium-independent vasomotion in large coronary arteries and in the microcirculation after cardiac transplantation. Eur Heart J. 1994;15:1486-1493.
36. Valantine HA. Role of lipids in allograft vascular disease: a multicenter study of intimal thickening detected by intravascular ultrasound. J Heart Lung Transplant 1995;14:S234-S237.
37. Tenkanen L, Pietila K, Manninen V, Manttari M. The triglyceride issue revisited: findings from the Helsinki Heart Study. Arch Intern Med. 1994;154:2712-2720.
38. Valantine HA, Rickenbacher P, Kemma M. Metabolic abnormalities characteristic of syndrome X and microvascular coronary artery disease are associated with cardiac allograft vascular disease. Circulation. In press.
39. Grattan MT, Moreno-Cabral CE, Stames VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA. 1989;261:3561-3566.
40. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with human leukocyte antigen-DR β-chain: a means for graft rejection and immunosuppression. J Virol. 1988;62:100-105.
41. Briggs B, Vook N, Knight D, Sedmak D. Molecular mechanisms of adhesion molecule modulation by human cytomegalovirus. Transplant Proc. In press.
42. Seir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. Potential role of human cytomegalovirus and p52 interaction in coronary restenosis. Science. 1994;165:391-394.
43. Costanzo MR. Heart transplantation. Curr Opin Cardiol. 1995;10: 155-158. Editorial.
44. Gulizia JM. Kandolf R, Kendall TJ, Thieszen SL, Wilson JE, Radio SJ, Costanzo MR, Winters GL, Miller LL, McManus BM. Infrequency of cytomegalovirus genome in coronary arteriopathy of human heart allografts. Am J Pathol. 1995;147:461-475.
45. Ardehali A, Laks H, Drinkwater DC, Kato NS, Permut LC, Grant PW, Aharon AS, Drake TA. Expression of major histocompatibility antigens and vascular adhesion molecules on human cardiac allografts preserved in University of Wisconsin solution. J Heart Lung Transplant. 1993;12:1044-1052.
46. Day JD, Rayburn BK, Gaudin PB, Baldwin WM III, Lowenstein CJ, Kasper EK, Baugham KL, Baumgartner WA, Hutchins GM, Hruban RH. Cardiac allograft vasculopathy: the central role of ischemia-induced endothelial cell injury. J Heart Lung Transplant. 1995;14:S142-S149.
47. Land W, Messmer K. The impact of ischemic/reperfusion injury on specific and non-specific early and late chronic events after organ transplantation. Transplant Rev. 1996;10:108-127.
48. Smart FW, Ballantyne CM, Cocanougher B, Farmer JA, Sekela ME, Noon GP, Young JB. Insensitivity of noninvasive tests to detect coronary artery vasculopathy after heart transplantation. Am J Cardiol. 1991;67:243-247.
49. Akosah KO, Mohanty PK, Funai JT, Jesse RL, Minisi AJ, Crandall CW, Kirchberg D, Guerraty A, Salter D. Noninvasive detection of transplant coronary artery disease by dobutamine stress echocardiography. J Heart Lung Transplant. 1994;13:1024-1038.
50. Cohn JM, Wilensky RL, O'Donnell JA, Bourdillon PDV, Dilon JC, Feigenbaum H. Exercise echocardiography, angiography, and intracoronary ultrasound after cardiac transplantation. Am J Cardiol. 1996;77:1216-1219.
51. Johnson DE, Aldermann EL, Schroeder JS, Silvermann JF, Hunt SA, De Campli WM, Stinson EB, Billingham M. Transplant coronary artery disease: histopathological correlations with angiographic morphology. J Am Coll Cardiol. 1991;17:449-457.
52. St. Goar FG, Pinto FJ, Aldermann EL, Valantine HA, Schroeder JS, Gao SZ, Stinson EB, Popp RL. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of angiographically silent intimai thickening. Circulation. 1992;85:979-987.
53. von Scheidt W, Ziegler U, Kemkes BM, Erdmann E. Heart transplantation: hemodynamics over a five-year period. J Heart Lung Transplant. 1991;10:342-350.
54. Keogh AM, Valantine HA, Hunt SA, Schroeder JS, McIntosh N, Oyer PE, Stinson EB. Impact of proximal or midvessel discrete coronary artery stenoses on survival after heart transplantation. J Heart Lung Transplant. 1992;11:892-901.
55. Tuzcu EM, De Franco AC, Goormastic M, Hobbs RE, Rincon G, Bott-Silverman C, McCarthy P, Stewart R, Mayer E, Nissen SE. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol. 1996;27:839-846.
56. Tuzcu EM, Hobbs RE, Rincon G, Bott-Silverman C, de Franco AC, Robinson K, McCarthy PM, Stewart RW, Guyer S, Nissen SE. Occult and frequent transmission of atherosclerotic coronary disease with cardiac transplantation: insights from intravascular ultrasound. Circulation. 1995;91:1706-1713.
57. Botas J, Pinto FJ, Chenzbraun A, Liang D, Schroeder JS, Oesterle SN, Alderman EL, Popp RL, Yeung AC. Influence of preexistent donor coronary artery disease on the progression of transplant vasculopathy: an intravascular ultrasound study. Circulation. 1995; 92:1126-1132.
58. Rickenbacher PR, Pinto FJ, Lewis NP, Hunt SA, Aldermann EL, Schroeder JS, Stinson EB, Brown BW, Valantine HA. Prognostic importance of intimal thickness as measured by intracoronary ultrasound after cardiac transplantation. Circulation. 1995;92: 3445-3452.
59. Mehra MR, Ventura HO, Stapleton DD, Smart FW, Collins TJ, Ramee SR. Presence of severe intimai thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy. J Heart Lung Transplant. 1995;14:632-639.
60. Fish RD, Nabel EG, Selwyn AP, Ludmer PL, Mudge GH, Kirsshenbaum JM, Schoen FJ, Alexander RW, Ganz P. Response of coronary arteries of transplant patients to acetylcholine. J Clin Invest. 1988;81:21-31.
61. Hartmann A, Mazzilli N, Weis M, Olbrich HG, Burger W, Satter P. Time course of endothelial function in epicardial conduit coronary arteries and in the microcirculation in the long-term follow-up after cardiac transplantation. Int J Cardiol. 1996;53:127-136.
62. Weis M, Hartmann A, Marzzilli N, Olbrich HG, Burger W, Satter P. Variations of segmental endothelium dependent and endothelium independent vasomotor tone in the long term follow up after cardiac transplantation (qualitative changes in endothelial function). J Am Coll Cardiol. 1995;2:430A. Abstract.
63. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue activator and the development of coronary artery disease in heart-transplant recipients. N Engl J Med. 1995;333:1111-1116.
64. Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Intern Med. 1994;235:317-327.
65. Davis SF, Yeung AC, Meredith I, Charbonneau F, Ganz P, Selwyn AP, Anderson TJ. Early endothelial dysfunction predicts the development of transplant coronary artery disease at 1 year post-transplant. Circulation. 1996;93:457-462.
66. Yeung AC, Anderson T, Meredith I, Uehata A, Ryan TJ, Selwyn AP, Mudge GH, Ganz P. Endothelial dysfunction in the development and detection of transplant coronary artery disease. J Heart Lung Transplant. 1992;11:S69-S73.
67. Treasure CB, Vita JA, Ganz P, Ryan TJ Jr, Schoen FJ, Vekshtein VI, Yeung AC, Mudge GH, Alexander RW, Selwyn AP, Fish RD. Loss of coronary microvascular response to acetylcholine in cardiac transplant patients. Circulation. 1992;86:1156-1164.
68. Nitenberg A, Aptecar E, Benvenuti C, Benhaiem N, Tavolaro O, Loisance D, Cachera JP. Effects of time and previous acute rejection episodes on coronary vascular reserve in human heart transplant recipients. J Am Coll Cardiol. 1992;20:1333-1338.
69. Mullins PA, Chauhan A, Sharples L, Cary NR, Large SR, Wallwork J, Schofield PM. Impairment of coronary flow reserve in orthotopic cardiac transplant recipients with minor coronary occlusive disease. Br Heart J. 1992;68:266-271.
70. Weis M, Hartmann A, Olbrich HG, Schacherer C, Wiemer J, Hör G, Zeiher AM. Prognostic significance of coronary flow reserve on left ventricular ejection fraction in heart transplant patients. Circulation. 1995;92(suppl I):I-245. Abstract.
71. Vekshtein VI, Alexander RW, Yeung AC, Plappert T, St. John Sutton MG, Ganz P. Coronary atherosclerosis is associated with left ventricular dysfunction and dilation in aortic stenosis. Circulation. 1990;82:2068-2074.
72. Clausell N, Butany J, Molossi S, Lonn E, Gladstone P, Rabinovitch M, Daly PA. Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. J Am Coll Cardiol. 1995;26:110-119.
73. von Scheidt W, Koglin J, Weis M, Gross T, Meiser BM, Überfuhr P. Epicardial and microvascular manifestations of transplant vasculopathy: two distinct entities. J Heart Lung Transplant. 1997; 16:85. Abstract.
74. Schroeder JS, Gao SZ, Alderman EL, Hunt SA, Johnstone I, Boothroyd DB, Wiederhold V, Stinson EB. A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients. N Engl J Med. 1993;328:164-170.
75. Ritz MA, Lüscher TF, Bühler FR. Different potency of endothelium derived relaxing factors against thromboxane and endothelin-1 in coronary arteries: comparison with nitrovasodilator and calcium antagonists. Coron Artery Dis. 1992;2:1001-1008.
76. Takami H, Backer CL, Crawford SE, Pahl E, Mavroudis C. Diltiazem preserves direct vasodilator response but fails to suppress intimai proliferation in rat allograft coronary disease. J Heart Lung Transplant. 1996;15:67-77.
77. Mehra MR, Ventura HO, Smart FW, Collins TJ, Ramee SR, Stapleton DD. An intravascular ultrasound study of the influence of angiotensin-converting enzyme inhibitors and calcium entry blockers on the development of cardiac allograft vasculopathy. Am J Cardiol. 1995;75:853-854.
78. Kobayashi J, Crawford SE, Backer CL, Zales VR, Takami H, Hsueh C, Huang L, Mavroudis C. Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation. 1993;88:286-290.
79. Yang Z, Arnet U, von Segesser L, Siebenmann R, Turina M, Lüscher TF. Different effects of angiotensin-converting enzyme inhibition in human arteries and veins. J Cardiovasc Pharmacol. 1993;22:517-522.
80. Lewis EJ, Hunsicker LG, Bain RP, Roihde RD, and the Collaborative Study Group. The effeet of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329: 1456-1462.
81. von der Leyen H, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 1995;92:1137-1141.
82. Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP, Alderman EL. Effect of L-arginine on coronary endothelial function in cardiac transplant patients. Circulation. 1994;89: 1615-1623.
83. Lou H, Kodama T, Wang YN, Katz NM, Foegh ML. L-Arginine modulates vascular cell proliferative response to IGF-I and IL-6 in cardiac transplant recipients. J Heart Lung Transplant. 1996; 15(part 2):S39. Abstract.
84. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, Chia D, Terasaki PI, Sabad A, Cogert GA, Troisan K, Hamilton MA, Moriguchi JD, Kawata N, Hage A, Drinkwater DC, Stevenson LW. Effects of pravastatin on outcome after cardiac transplantation. N Engl J Med. 1995;333: 621-627.
85. Doyle JW, Kandutsch AA. Requirement for mevalonate in cycling cells: quantitative and temporal aspects. J Cell Physiol. 1988;137: 133-140.
86. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol. 1989;139:550-557.
87. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicity by interleukin-2. J Cell Physiol. 1990;145:244-252.
88. Fyfe AI, Harper CM. HMG-CoA reductase inhibitors activated monocyte/macrophage surface expression of class I and II HLA molecules. Circulation. 1995;92(suppl I):I-498. Abstract.
89. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C, La Placa P, Patrono C. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995;15: 247-251.
90. Lou H, Kodama T, Maurice PF, Kolatkar NS, Wang Y, Katz NM, Foegh ML. Angiopeptin suppresses T-lymphocyte, macrophage infiltration and MHC class II antigen in the coronary artery following cardiac transplantation. Circulation. 1995;92(suppl I):I-704. Abstract.
91. Foegh ML. Angiopeptin: a treatment for accelerated myointimal hyperplasia. J Heart Lung Transplant. 1992;11:S28-S31.
92. Meiser BM, von Scheidt W, Mair H, Kur F, Detter C, Überfuhr P, Kreuzer E, Foegh M, Reichart B. Short-term angiopeptin treatment significantly reduces intimal proliferation after heart transplantation. J Heart Lung Transplant. 1995;14(part 2):S56. Abstract.
93. Russell ME, Hancock WH, Wallace AF, Glysing-Jensen T. Willett TA, Sayegh MH. Chronic cardiac rejection in the Lew to F344 rat model. J Clin Invest. 1996;97:833-838.
94. Mehra MR, Ventura HO, Chambers R, Smart FW, Stapleton DD. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal. Circulation. 1995;92(suppl I):I-245. Abstract.
95. Nair RV, Morris RE. Immunosuppression in cardiac transplantation: a new area in immunopharmacology. Curr Opin Cardiol. 1995;10:207-217.
96. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet. 1991;338: 1297-1298.
97. Arai S, Taramato S, Senoo Y. The impact of FK506 on graft coronary disease of rat cardiac allograft: a comparison with cyclosporine. J Heart Lung Transplant. 1992;11:757-762.
98. Wu GD, Cramer DV, Chapman FA, Cajulis E, Wang HK, Starzl TE, Makowa L. FK 506 inhibits the development of transplant arteriosclerosis. Transplant Proc. 1991;23:3272-3274.
99. Pham SM, Kormos RL, Hattler BG, Kawai A, Tsamandas AC, Demetris AJ, Murali S, Fricker FJ, Chang HC, Jain AB, Starzl TE, Hardesty RL, Griffith BP. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg. 1996;11:764-772.
100. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse B, Billingham ME, Morris RE. Treatment with rapamycin and mycophenolate acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation. 1995;59:655-661.
101. Hauser I, Johnson DR, Thevenod F. Mycophenolate mofetil increases tumor necrosis factor α (TNFα) induced expression of vascular cell adhesion molecule 1 (VCAM-1) and of E-selectin on human venous endothelial cells. FASEB J. 1996;10:3612. Abstract.
102. Nagamine S, Ohmi M, Tabayashi K, Iguchi A, Mohri H. Effects of cyclosporine and 15-deoxyspergualin on coronary arteriosclerosis after heart transplantation in the rat. J Heart Lung Transplant. 1994;13:895-898.
103. Räisänen-Sokolowski A, Yilmaz S, Tufveson G, Häyry P. Partial inhibition of allograft arteriosclerosis (chronic rejection) by 15-deoxyspergualin. Transplantation. 1994;57:1772-1777.
104. Schmid C, Heeman U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allograft. Transplantation. 1995;60:729-733.
105. Xiao F, Chong A, Shen J. Pharmacologically induced regression of chronic transplant rejection. Transplantation. 1995;60:1065-1072.
106. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res. 1995;76:412-417.
107. Halle AA III, Wilson RF, Massin EK, Bourge RC, Stadius ML, Johnson MR, Wray RB, Young JB, Davies RA, Walford GD, Miller LW, Deligonul U, Rincon G, Kubo SH, DiSciascio G, Crandall CC, Cowley MJ, Vetrovec GW. Coronary angioplasty in cardiac transplant patients: results of a multicenter study. Circulation. 1992;86:458-462.
108. von Scheidt W, Überfuhr P, Reichart B, Steinbeck G. The role of PTCA in the management of focal critical lesions in transplant coronary artery disease. Transplant Proc. 1995;3:1936-1938.
109. Jain SP, Ventura HO, Ramee SR, Collins TJ, Isner JM, White CJ. Directional coronary atherectomy in heart transplant recipients. J Heart Lung Transplant. 1993;12:819-823.
110. Copeland JG, Butman SM, Sehti G. Successful coronary artery bypass grafting for high-risk left main coronary artery atherosclerosis after cardiac transplantation. Ann Thorac Surg. 1990;49: 106-110.
111. Halle AA III, DiSciascio G, Massin EK, Wilson RF, Johnson MR. Sullivan HJ, Bourge RC, Kleiman NS, Miller LW, Aversano TR, Wray RB, Hunt SA, Weston MW, Davies RA, Rincon G, Crandall CC, Cowley MJ, Kubo SH, Fisher SG, Vetrovec GW. Coronary angioplasty, atherectomy and bypass surgery in cardiac transplant recipients. J Am Coll Cardiol. 1995;26:120-128.
112. March RJ, Guynn T. Cardiac allograft vasculopathy: the potential role for transmyocardial laser revascularization. J Heart Lung Transplant. 1995;14:S242-S246.
113. Gao SZ, Schroeder JS, Hunt S, Stinson EB. Retransplantation for severe accelerated coronary artery disease in heart transplant recipients. Am J Cardiol. 1988;62:876-881.
114. Ensley RD, Hunt S, Taylor DO, Renlund DG, Menlove RL, Karwande SV, O'Connell JB, Barr ML, Michler RE, Copeland JG, Miller LW, The Registry of the International Society for Heart and Lung Transplantation, and Contributing Investigators. Predictors of survival after repeat heart transplantation. J Heart Lung Transplant. 1992;11:S142-S158.
115. Hosenpud JD, Novick RJ, Breen TJ, Daily OP. The Registry of the International Society for Heart and Lung Transplantation: Eleventh Official Report - 1994. J Heart Lung Transplant. 1994;13: 561-570.